MA37666B1 - Sel de camsylate - Google Patents
Sel de camsylateInfo
- Publication number
- MA37666B1 MA37666B1 MA37666A MA37666A MA37666B1 MA 37666 B1 MA37666 B1 MA 37666B1 MA 37666 A MA37666 A MA 37666A MA 37666 A MA37666 A MA 37666A MA 37666 B1 MA37666 B1 MA 37666B1
- Authority
- MA
- Morocco
- Prior art keywords
- dementia
- salt
- disease
- camsylate salt
- senile dementia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne un sel de camsylate de la (1r,1'r,4r)-4-méthoxy-5"-méthyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'h-dispiro[cyclohexane-1,2'-inden-1'2'-imidazole]-4"-amine, des compositions pharmaceutiques contenant le sel et des utilisations thérapeutiques du sel pour traiter des pathologies associées à l'?ß telles que la maladie d'alzheimer, le syndrome de down, l'angiopathie ß-amyloïde et des états tels que la démence y compris la démence d'origine mixte vasculaire et dégénérative, la démence pré-sénile, la démence sénile et la démence associée à la maladie de parkinson, la paralysie supranucléaire progressive ou la dégénérescence cortico-basale.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261662592P | 2012-06-21 | 2012-06-21 | |
PCT/GB2013/051606 WO2013190302A1 (fr) | 2012-06-21 | 2013-06-20 | Sel de camsylate |
Publications (2)
Publication Number | Publication Date |
---|---|
MA37666A1 MA37666A1 (fr) | 2016-04-29 |
MA37666B1 true MA37666B1 (fr) | 2016-12-30 |
Family
ID=48746084
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39259A MA39259B1 (fr) | 2012-06-21 | 2013-06-20 | Sel de camsylate |
MA37666A MA37666B1 (fr) | 2012-06-21 | 2014-12-10 | Sel de camsylate |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39259A MA39259B1 (fr) | 2012-06-21 | 2013-06-20 | Sel de camsylate |
Country Status (42)
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
WO2013054108A1 (fr) | 2011-10-10 | 2013-04-18 | Astrazeneca Ab | Inhibiteurs de mono fluoro-bêta-secretase |
US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US9000182B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US9000185B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
US10053453B2 (en) | 2014-10-07 | 2018-08-21 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
JP6546410B2 (ja) * | 2015-02-23 | 2019-07-17 | ローム株式会社 | 電力供給装置、acアダプタ、acチャージャ、電子機器および電力供給システム |
AR107783A1 (es) | 2016-03-15 | 2018-06-06 | Lilly Co Eli | Terapia de combinación |
CN109195630A (zh) * | 2016-03-15 | 2019-01-11 | 阿斯利康(瑞典)有限公司 | 用于治疗与淀粉样蛋白β累积相关的病症的BACE抑制剂和抗体或抗原结合片段的组合 |
AU2020234033B2 (en) * | 2019-03-14 | 2023-07-13 | Astrazeneca Ab | Lanabecestat for weight loss |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100452491B1 (ko) * | 2001-03-29 | 2004-10-12 | 한미약품 주식회사 | 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법 |
JP4273406B2 (ja) | 2001-06-01 | 2009-06-03 | 小野薬品工業株式会社 | アルドース還元酵素阻害剤を有効成分とする脱髄性疾患または脱髄を伴う疾患治療剤 |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
EP1729771B1 (fr) | 2004-03-22 | 2009-10-14 | Eli Lilly & Company | Derives de pyridyle et leur utilisation en tant qu'antagonistes du recepteur de mglu5 |
WO2006138264A2 (fr) | 2005-06-14 | 2006-12-28 | Schering Corporation | Inhibiteurs d'aspartyl protease |
CN101360716A (zh) | 2005-11-21 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | 新颖的2-氨基-咪唑-4-酮化合物及其在制备用于治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物中的用途 |
TW200734311A (en) * | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
CA2633992A1 (fr) | 2005-12-21 | 2007-07-05 | Boehringer Ingelheim International Gmbh | Derives de la pyrimidine utiles comme inhibiteurs de la pkc-theta |
WO2007100536A1 (fr) | 2006-02-24 | 2007-09-07 | Wyeth | COMPOSES DE DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] POUR L'INHIBITION DE LA β-SECRETASE |
AR061264A1 (es) | 2006-06-12 | 2008-08-13 | Schering Corp | Inhibidores de aspartil-proteasas derivados de pirimidina, composiciones farmaceuticas que los contienen y usos para tratar enfermedades cognitivas o neurodegenerativas, y como inhibidores del virus vih. |
WO2008076044A1 (fr) | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Nouveaux 2-amino-5, 5-diaryl-imidazol-4-ones |
JP2010517963A (ja) | 2007-02-01 | 2010-05-27 | グラクソ グループ リミテッド | 神経学的および神経精神病学的障害の治療におけるGlyT1トランスポーター阻害薬としての8−オキサ−1,4−ジアザスピロ[4,5]デク−3−エン−1−イルおよび1,4,8−トリアザスピロ[4,5]デク−3−エン−1−イルアセトアミド誘導体 |
RU2009144998A (ru) | 2007-05-07 | 2011-06-20 | Шеринг Корпорейшн (US) | Модуляторы гамма-секретазы |
WO2009100169A1 (fr) | 2008-02-06 | 2009-08-13 | Glaxo Group Limited | Pharmacophores duals, antagonistes des récepteurs muscariniques et inhibiteurs de l'activité pde4 |
FR2929943B1 (fr) * | 2008-04-15 | 2010-09-24 | Inst Rech Developpement Ird | Sels de quinoleines 2-substituees |
AU2009277485B2 (en) | 2008-07-28 | 2013-05-02 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
US8450308B2 (en) | 2008-08-19 | 2013-05-28 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
PE20110805A1 (es) | 2008-09-11 | 2011-11-09 | Amgen Inc | Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso |
CA2753730C (fr) | 2009-03-13 | 2020-12-22 | Vitae Pharmaceuticals, Inc. | Inhibiteurs de beta-secretase |
AR077365A1 (es) | 2009-07-02 | 2011-08-24 | Astrazeneca Ab | Derivados de imidazol para el tratamiento de enfermedades mediadas por la inhibicion de la formacion de abeta |
AR077447A1 (es) | 2009-07-02 | 2011-08-31 | Astrazeneca Ab | Compuestos inhibidores de beta-secretasa, utiles para el tratamiento de enfermedades neurodegenerativas |
CN102812005B (zh) | 2010-02-24 | 2014-12-10 | 生命医药公司 | β-分泌酶抑制剂 |
AR080865A1 (es) | 2010-03-31 | 2012-05-16 | Array Biopharma Inc | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. |
WO2011130741A1 (fr) | 2010-04-16 | 2011-10-20 | Array Biopharma Inc. | Composés pour le traitement de maladies neurodégénératives |
WO2012019056A1 (fr) | 2010-08-05 | 2012-02-09 | Amgen Inc. | Composés d'amino-iso-indole, d'amino-aza-iso-indole, d'amino-dihydro-isoquinoléine et d'amino-benzoxazine en tant que modulateurs de la bêta-sécrétase et leurs méthodes d'utilisation |
UY33627A (es) | 2010-09-24 | 2013-04-30 | Array Biopharma Inc | Compuestos para tratar enfermedades neurodegenerativas |
WO2012071458A1 (fr) | 2010-11-22 | 2012-05-31 | Array Biopharma Inc. | Inhibiteurs hétérocycliques de la bêta-secrétase pour le traitement de maladies neurodégénératives |
US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
WO2013054108A1 (fr) | 2011-10-10 | 2013-04-18 | Astrazeneca Ab | Inhibiteurs de mono fluoro-bêta-secretase |
US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US9000185B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US9000182B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
-
2013
- 2013-06-13 US US13/916,754 patent/US10548882B2/en active Active
- 2013-06-19 AR ARP130102162 patent/AR091495A1/es unknown
- 2013-06-20 MA MA39259A patent/MA39259B1/fr unknown
- 2013-06-20 IN IN10088DEN2014 patent/IN2014DN10088A/en unknown
- 2013-06-20 HU HUE13733415A patent/HUE033376T2/en unknown
- 2013-06-20 EP EP13733415.7A patent/EP2864316B1/fr active Active
- 2013-06-20 PT PT137334157T patent/PT2864316T/pt unknown
- 2013-06-20 RS RS20170236A patent/RS55815B1/sr unknown
- 2013-06-20 SI SI201330561A patent/SI2864316T1/sl unknown
- 2013-06-20 KR KR1020147035069A patent/KR102123708B1/ko active IP Right Grant
- 2013-06-20 RU RU2014148305A patent/RU2638175C2/ru active
- 2013-06-20 LT LTEP13733415.7T patent/LT2864316T/lt unknown
- 2013-06-20 CA CA2875589A patent/CA2875589C/fr active Active
- 2013-06-20 SG SG11201407934UA patent/SG11201407934UA/en unknown
- 2013-06-20 NZ NZ727045A patent/NZ727045A/en not_active IP Right Cessation
- 2013-06-20 MX MX2014014709A patent/MX354214B/es active IP Right Grant
- 2013-06-20 BR BR112014031531-0A patent/BR112014031531B1/pt active IP Right Grant
- 2013-06-20 CN CN201380033030.6A patent/CN104411697B/zh active Active
- 2013-06-20 AP AP2017009693A patent/AP2017009693A0/en unknown
- 2013-06-20 NZ NZ702742A patent/NZ702742A/en not_active IP Right Cessation
- 2013-06-20 UA UAA201412619 patent/UA114196C2/uk unknown
- 2013-06-20 WO PCT/GB2013/051606 patent/WO2013190302A1/fr active Application Filing
- 2013-06-20 AU AU2013279109A patent/AU2013279109B2/en active Active
- 2013-06-20 ES ES13733415.7T patent/ES2618939T3/es active Active
- 2013-06-20 AP AP2014008137A patent/AP2014008137A0/xx unknown
- 2013-06-20 CN CN201610570484.2A patent/CN106279102A/zh active Pending
- 2013-06-20 BR BR122016014302-3A patent/BR122016014302B1/pt active IP Right Grant
- 2013-06-20 PL PL13733415T patent/PL2864316T3/pl unknown
- 2013-06-20 PE PE2014002451A patent/PE20150670A1/es active IP Right Grant
- 2013-06-20 DK DK13733415.7T patent/DK2864316T3/en active
- 2013-06-20 EP EP16162104.0A patent/EP3064494A1/fr not_active Withdrawn
- 2013-06-20 JP JP2015517850A patent/JP2015520221A/ja active Pending
- 2013-06-21 TW TW106115007A patent/TWI639591B/zh not_active IP Right Cessation
- 2013-06-21 TW TW102122259A patent/TWI588140B/zh not_active IP Right Cessation
-
2014
- 2014-11-25 DO DO2014000268A patent/DOP2014000268A/es unknown
- 2014-11-25 TN TN2014000491A patent/TN2014000491A1/fr unknown
- 2014-12-08 IL IL236131A patent/IL236131A0/en active IP Right Grant
- 2014-12-10 MA MA37666A patent/MA37666B1/fr unknown
- 2014-12-11 CR CR20140571A patent/CR20140571A/es unknown
- 2014-12-11 CL CL2014003374A patent/CL2014003374A1/es unknown
- 2014-12-16 PH PH12014502803A patent/PH12014502803B1/en unknown
- 2014-12-18 EC ECIEPI201432215A patent/ECSP14032215A/es unknown
- 2014-12-18 NI NI201400146A patent/NI201400146A/es unknown
- 2014-12-18 CO CO14278352A patent/CO7151486A2/es unknown
-
2015
- 2015-01-20 ZA ZA2015/00408A patent/ZA201500408B/en unknown
- 2015-07-22 HK HK15106985.7A patent/HK1206349A1/zh not_active IP Right Cessation
-
2016
- 2016-03-14 PH PH12016500498A patent/PH12016500498A1/en unknown
- 2016-04-29 CR CR20160202A patent/CR20160202A/es unknown
- 2016-06-28 AR ARP160101953A patent/AR105176A2/es unknown
-
2017
- 2017-03-06 HR HRP20170359TT patent/HRP20170359T1/hr unknown
- 2017-03-08 ME MEP-2017-61A patent/ME02633B/fr unknown
- 2017-03-13 CY CY20171100314T patent/CY1119505T1/el unknown
- 2017-11-03 AU AU2017254965A patent/AU2017254965B2/en not_active Ceased
-
2018
- 2018-02-09 JP JP2018021595A patent/JP6509393B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37666B1 (fr) | Sel de camsylate | |
MA37888B1 (fr) | Composition pharmaceutique enrobée contenant du régorafenib | |
MA39225A1 (fr) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tétrahydropyridines utilisées en tant qu'inhibiteurs de bace1 dans le traitement de la maladie d'alzheimer | |
MA40955B1 (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
MA35039B1 (fr) | Dérivés ramifiés de l'acide 3-phénylpropionique et leur utilisation | |
MA38146B1 (fr) | Nouveaux dérivés du benzimidazole comme antagonistes ep4 | |
MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
MA38661A1 (fr) | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine | |
MA37798B1 (fr) | 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes | |
EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
MX357383B (es) | Derivados de 5-(3-aminofenil)-5-alquil-5,6-dihidro-2h-[1,4]oxazin- 3-amina. | |
MA39171A1 (fr) | Dérivés d'hydroxy formamide et leur utilisation | |
MA38410A1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
WO2014014794A3 (fr) | Antagonistes des récepteurs aux minéralocorticoïdes | |
MA38307A1 (fr) | 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale | |
MA37524B1 (fr) | Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee | |
MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
CO7160082A2 (es) | Un método para mejorar la función hepática | |
MA37879B1 (fr) | Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant | |
EA201992055A1 (ru) | Ингибиторы бета-секретазы | |
MA44503B1 (fr) | Composés de pyrrolotriazine en tant qu'inhibiteurs de tam | |
PL415780A1 (pl) | Trans-(4R,5S,6R)-4-(benzo[d][1',3']-dioksol-5'-ylo)-5-(1-jodoetylo)-dihydrofuran oraz sposób jego otrzymywania | |
TH167610A (th) | อนุพันธ์ 6-ไดฟลูออโรเมทิล-5, 6 ไดไฮโดร-2h-[1,4]ออกซาซิน-3-เอมีน | |
MA37836B1 (fr) | Antagonistes du récepteur 5-ht3 | |
MA38849A1 (fr) | Nouveaux composés d'indazole pour le traitement du diabete et leur procede de preparation |